HPV related OPSCC has a distinct behavior and improved outcome. As immunotherapy has recently evolved into a new standard for advanced (SCCHN), trials for high-risk SCCHN have trended to encompass both HPV related and unrelated diseases. In this invited editorial, we question the wisdom of this approach and argue for the design of trials focused specifically on HPV related locally advanced oropharyngeal squamous cell carcinoma as a unique disease entity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460663PMC
http://dx.doi.org/10.1186/s41199-018-0035-7DOI Listing

Publication Analysis

Top Keywords

locally advanced
8
oropharyngeal squamous
8
squamous cell
8
cell carcinoma
8
advanced high-risk
4
hpv
4
high-risk hpv
4
hpv oropharyngeal
4
carcinoma opscc
4
opscc forgotten
4

Similar Publications

Background: Although substantial progress has been made in establishing evidence-based psychosocial clinical interventions and implementation strategies for mental health, translating research into practice-particularly in more accessible, community settings-has been slow.

Objective: This protocol outlines the renewal of the National Institute of Mental Health-funded University of Washington Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness Center, which draws from human-centered design (HCD) and implementation science to improve clinical interventions and implementation strategies. The Center's second round of funding (2023-2028) focuses on using the Discover, Design and Build, and Test (DDBT) framework to address 3 priority clinical intervention and implementation strategy mechanisms (ie, usability, engagement, and appropriateness), which we identified as challenges to implementation and scalability during the first iteration of the center.

View Article and Find Full Text PDF

Purpose: Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that targets exon 20 insertion (ex20ins) mutations in non-small cell lung cancer (NSCLC). This open-label, phase III trial (EXCLAIM-2: ClinicalTrials.gov identifier: NCT04129502) compared mobocertinib versus platinum-based chemotherapy as first-line treatment of ex20ins+ advanced/metastatic NSCLC.

View Article and Find Full Text PDF

Holography is capable of rendering three-dimensional scenes with full-depth control and delivering transformative experiences across numerous domains, including virtual and augmented reality, education, and communication. However, traditional holography presents 3D scenes with unnatural defocus and severe speckles due to the limited space bandwidth product of the spatial light modulator (SLM). Here, we introduce Motion Hologram, a holographic technique that accurately portrays photorealistic and speckle-free 3D scenes.

View Article and Find Full Text PDF

The Quality-of-Care Network (QCN), launched by WHO and partners, links global and national actors across several countries to improve maternal and newborn health. We conducted a prospective qualitative study to examine how QCN in Bangladesh, Ethiopia, Malawi and Uganda facilitated learning, sharing, and innovation within and between network countries. We conducted 227 key informant interviews with QCN actors at global, national, and facility levels iteratively in two to four rounds from June 2019 to March 2022.

View Article and Find Full Text PDF

The European regulatory system for plant protection products-cause of a "Silent Spring" or highly advanced and protective?

Integr Environ Assess Manag

January 2025

Industrieverband Agrar e. V. (IVA), Wissenschaft und Innovation, Frankfurt am Main, Germany.

Current publications that are shaping public perception repeatedly claim that residues of plant protection products (PPP) in the environment demonstrate gaps in assessing the exposure and effects of PPP, allegedly revealing the inability of the European regulatory system to prevent environmental contamination and damage such as biodiversity decline. The hypothesis is that environmental risk assessments rely on inappropriate predictive models that underestimate exposure and do not explicitly account for the impact of combinations of environmental stressors and physiological differences in stress responses. This article puts this criticism into context to allow for a more balanced evaluation of the European regulatory system for PPP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!